Development and Validation of an Automated Image-Based Deep Learning Platform for Sarcopenia Assessment in Head and Neck Cancer
Authors: Ye Zezhong , Saraf Anurag , Ravipati Yashwanth , Hoebers Frank , Catalano Paul J. , Zha Yining , Zapaishchykova Anna , Likitlersuang Jirapat , Guthier Christian , Tishler Roy B. , Schoenfeld Jonathan D. , Margalit Danielle N. , Haddad Robert I. , Mak Raymond H. , Naser Mohamed , Wahid Kareem A. , Sahlsten Jaakko , Jaskari Joel , Kaski Kimmo , Mäkitie Antti A. , Fuller Clifton D. , Aerts Hugo J. W. L. , Kann Benjamin H. 
Published: August 2023

Importance

Sarcopenia is an established prognostic factor in patients with head and neck squamous cell carcinoma (HNSCC); the quantification of sarcopenia assessed by imaging is typically achieved through the skeletal muscle index (SMI), which can be derived from cervical skeletal muscle segmentation and cross-sectional area. However, manual muscle segmentation is labor intensive, prone to interobserver variability, and impractical for large-scale clinical use.

Objective

To develop and externally validate a fully automated image-based deep learning platform for cervical vertebral muscle segmentation and SMI calculation and evaluate associations with survival and treatment toxicity outcomes.

Design, Setting, and Participants

For this prognostic study, a model development data set was curated from publicly available and deidentified data from patients with HNSCC treated at MD Anderson Cancer Center between January 1, 2003, and December 31, 2013. A total of 899 patients undergoing primary radiation for HNSCC with abdominal computed tomography scans and complete clinical information were selected. An external validation data set was retrospectively collected from patients undergoing primary radiation therapy between January 1, 1996, and December 31, 2013, at Brigham and Women’s Hospital. The data analysis was performed between May 1, 2022, and March 31, 2023.

Exposure

C3 vertebral skeletal muscle segmentation during radiation therapy for HNSCC.

Main Outcomes and Measures

Overall survival and treatment toxicity outcomes of HNSCC.

Results

The total patient cohort comprised 899 patients with HNSCC (median [range] age, 58 [24-90] years; 140 female [15.6%] and 755 male [84.0%]). Dice similarity coefficients for the validation set (n = 96) and internal test set (n = 48) were 0.90 (95% CI, 0.90-0.91) and 0.90 (95% CI, 0.89-0.91), respectively, with a mean 96.2% acceptable rate between 2 reviewers on external clinical testing (n = 377). Estimated cross-sectional area and SMI values were associated with manually annotated values (Pearsonr = 0.99;P &amp;lt; .001) across data sets. On multivariable Cox proportional hazards regression, SMI-derived sarcopenia was associated with worse overall survival (hazard ratio, 2.05; 95% CI, 1.04-4.04;P = .04) and longer feeding tube duration (median [range], 162 [6-1477] vs 134 [15-1255] days; hazard ratio, 0.66; 95% CI, 0.48-0.89;P = .006) than no sarcopenia.

Conclusions and Relevance

This prognostic study’s findings show external validation of a fully automated deep learning pipeline to accurately measure sarcopenia in HNSCC and an association with important disease outcomes. The pipeline could enable the integration of sarcopenia assessment into clinical decision making for individuals with HNSCC.